80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
INHERIT Model: a tool to jointly improve health, environmental sustainability and Health Equity RIVM is involved in the Horizon2020 project INHERIT. The first article of the INHERIT project has been published, lead-authored by RIVM.
RIVM supports WHO in national capacity building for measuring foodborne disease burden RIVM’s Collaborating Centre for Risk Assessment of Pathogens in Food and Water was invited to WHO’s side event during the 41st Codex Alimentarius Commission on July 4th 2018.
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Risks of potential release of genetically modified mosquitoes evaluated On Saba, a Dutch Caribbean island, diseases such as dengue, chikungunya and zika can be reduced by the use of genetically modified mosquitoes.